```html

Quasi‑miliary Tuberculosis

Overview

Quasi‑miliary tuberculosis (QMT) is a rare form of pulmonary tuberculosis that mimics classic miliary TB on imaging but does not fulfill all of the classic criteria. In QMT, numerous tiny (<2 mm) nodules are scattered throughout both lungs, often with a slightly larger “ground‑glass” component. The disease usually arises from a re‑activation of latent Mycobacterium tuberculosis infection or from a heavily disseminated primary infection that has not yet become truly miliary.

• Who it affects: Adults aged 30‑60 years are most commonly reported, with a slight male predominance (≈60 %). Immunocompromised individuals (HIV, transplant recipients, patients on biologics) are at higher risk, but QMT also occurs in immunocompetent hosts.
• Prevalence: Precise global numbers are not available because QMT is usually grouped under “miliary‑type TB” in surveillance data. In high‑burden countries, miliary‑type presentations account for 1–2 % of all active TB cases, and QMT is thought to represent roughly a third of these (≈0.3–0.6 % of total TB cases) <sup>[1][2]</sup>.

Symptoms

The clinical picture of QMT can be subtle and often overlaps with other pulmonary conditions. The most commonly reported symptoms are:

• Fever – low‑grade to high‑grade, often intermittent and worse in the evening.
• Night sweats – drenching sweats that soak clothing or bedding.
• Weight loss – unintended loss of ≥5 % body weight over weeks to months.
• Fatigue / malaise – generalized weakness, sometimes severe enough to limit daily activities.
• Cough – usually dry or minimally productive; may become productive with serous sputum.
• Chest pain – pleuritic or vague discomfort, especially on deep inhalation.
• Dyspnea – shortness of breath on exertion; severe cases may have resting dyspnea.
• Hemoptysis – rare, but can occur if bronchial erosion happens.
• Generalized lymphadenopathy – enlarged neck or mediastinal nodes in some patients.
• Abdominal symptoms – occasional nausea, anorexia, or mild abdominal pain if the disease spreads.

Because the nodular pattern is often discovered incidentally on a chest X‑ray or CT performed for another reason, many patients present without classic “TB‑type” symptoms.

Causes and Risk Factors

Underlying cause

QMT is caused by the same bacterium as all forms of tuberculosis: Mycobacterium tuberculosis. The “quasi‑miliary” pattern results from a high burden of organisms spreading through the pulmonary arterial or lymphatic circulation, creating innumerable tiny granulomas that are too small to coalesce into larger cavitary lesions.

Risk factors

• Immunosuppression: HIV infection (especially CD4 < 200 cells/µL), chronic corticosteroid use, biologic agents (TNF‑α inhibitors), organ transplantation.
• Recent exposure to active TB: living or working in households, prisons, or shelters with a TB case.
• Previous latent TB infection (LTBI): Reactivation is a frequent pathway.
• Malnutrition or low body‑mass index: impairs cell‑mediated immunity.
• Chronic lung disease: COPD, silicosis, or prior TB scarring.
• Substance use: excessive alcohol, intravenous drug use, or smoking.
• Age: Adults 30‑60 years, though children and the elderly can be affected.

Diagnosis

The diagnosis of QMT relies on a combination of clinical suspicion, imaging, microbiological confirmation, and sometimes histopathology.

Imaging

• Chest X‑ray: Diffuse, fine, uniformly distributed micronodules (“snowstorm” appearance) without large consolidations.
• High‑resolution CT (HRCT): Shows innumerable 1–2 mm centrilobular nodules, often with a perilymphatic distribution and mild ground‑glass opacity. The pattern helps differentiate QMT from classic miliary TB (which tends to involve the entire secondary lobule) and from other diffuse nodular diseases (e.g., sarcoidosis, hypersensitivity pneumonitis).

Microbiological tests

• Sputum smear microscopy: Ziehl‑Neelsen or fluorescent staining for acid‑fast bacilli (AFB). Sensitivity is modest (≈40‑60 %) in QMT because the bacterial load in sputum can be low.
• Sputum culture: Gold standard; grows M. tuberculosis in 2‑6 weeks (solid media) or 1‑2 weeks (liquid systems such as MGIT).
• Nucleic acid amplification tests (NAATs): Xpert MTB/RIF Ultra provides rapid detection (<2 h) and rifampicin resistance status with higher sensitivity than smear, especially valuable for QMT <sup>[3]</sup>.
• Bronchoscopy with bronchoalveolar lavage (BAL): Recommended when sputum is negative but suspicion remains high. BAL fluid is subjected to the same smear, culture, and NAATs.

Additional investigations

• Interferon‑γ release assay (IGRA) or tuberculin skin test (TST): Helps identify latent infection but cannot confirm active disease.
• Complete blood count (CBC): May show mild anemia or leukocytosis.
• Blood chemistry: Liver function tests baseline before initiating therapy.
• HIV testing: Recommended for all patients with suspected TB.

Treatment Options

Management follows standard anti‑tubercular therapy (ATT) guidelines, with modifications based on drug susceptibility, patient comorbidities, and disease severity.

First‑line regimen (drug‑susceptible TB)

1. Intensive phase (2 months): Isoniazid (INH) + Rifampicin (RIF) + Pyrazinamide (PZA) + Ethambutol (EMB).
2. Continuation phase (4–7 months): INH + RIF. For QMT, many clinicians extend the continuation phase to 7 months to ensure sterilization of the numerous micro‑lesions.

Drug‑resistant TB

• Multidrug‑resistant (MDR‑TB): Requires a regimen containing a fluoroquinolone (e.g., levofloxacin) plus a second‑line injectable (amikacin or kanamycin) or newer agents (bedaquiline, delamanid) for ≥18 months.
• Extensively drug‑resistant (XDR‑TB): Managed with individualized, susceptibility‑guided combinations; often includes bedaquiline, linezolid, and pretomanid.

Adjunctive measures

• Corticosteroids: Not routinely indicated but may be used if there is significant inflammatory pneumonitis or concurrent meningitis.
• Vitamin D supplementation: Some studies suggest modest benefit in speeding sputum conversion <sup>[4]</sup>.
• Nutrition support: High‑protein, calorie‑dense diet; consider oral nutritional supplements for weight loss ≥5 %.

Lifestyle & adherence

• Directly observed therapy (DOT) is strongly recommended to improve adherence.
• Avoid alcohol and smoking during treatment as they increase hepatotoxic risk.
• Notify the healthcare team promptly if side effects such as visual changes (ethambutol), peripheral neuropathy (INH), or jaundice (PZA, RIF) develop.

Living with Quasi‑miliary Tuberculosis

Daily management tips

• Medication schedule: Take drugs on an empty stomach (usually morning) with plenty of water; set alarms or use a pill‑box.
• Monitor side effects: Record any new symptoms (e.g., numbness, skin rash, dark urine) and report them.
• Follow‑up appointments: Monthly clinic visits for sputum testing, liver function monitoring, and weight check.
• Infection control at home: Keep windows open for ventilation, wear a surgical mask when coughing, and practice frequent hand hygiene.
• Physical activity: Light aerobic exercise (walking, stretching) as tolerated; avoid strenuous activity if dyspnea is severe.
• Nutrition: Aim for 1.5–2 g protein/kg body weight daily; include iron‑rich foods (lean meat, legumes) to counter anemia.
• Psychosocial support: Join a TB support group, and consider counseling if anxiety or depression arise.

Medication adherence tools

• Smartphone reminder apps (e.g., Medisafe, MyTherapy).
• Family member or friend as a “treatment buddy.”
• Community health worker visits for DOT.

Prevention

• Screen high‑risk populations: Routine IGRA/TST for healthcare workers, persons living with HIV, and close contacts of active TB cases.
• Treat latent TB infection (LTBI): Isoniazid for 6–9 months or rifampicin/isoniazid weekly for 3 months reduces progression to active disease by ≈90 % <sup>[5]</sup>.
• Vaccination: BCG vaccine offers variable protection against disseminated TB in children; its effect on adult pulmonary forms, including QMT, is modest.
• Infection control in congregate settings: UV germicidal irradiation, negative‑pressure rooms, and respiratory etiquette.
• General health measures: Adequate nutrition, smoking cessation, limiting alcohol, and managing chronic diseases (diabetes, renal failure).

Complications

If QMT is left untreated or treatment is delayed, the following complications may develop:

• Progression to classic miliary TB: Involvement of extrapulmonary sites (meninges, bone marrow, liver, spleen).
• Respiratory failure: Diffuse alveolar damage leading to hypoxemia.
• Pulmonary fibrosis: Permanent scarring that reduces lung capacity.
• Secondary bacterial infection: Due to damaged airway epithelium.
• Drug‑induced hepatotoxicity: Can be severe, especially when multiple hepatotoxic drugs are used.
• Mortality: Reported case‑fatality for untreated miliary‑type TB ranges from 20–50 %; early treatment reduces mortality to <5 % <sup>[6]</sup>.

When to Seek Emergency Care

References

1. World Health Organization. Global Tuberculosis Report 2023. Geneva: WHO; 2023.
2. CDC. Tuberculosis (TB) in the United States, 2022. Atlanta: CDC; 2023.
3. World Health Organization. Xpert MTB/RIF Ultra: Policy Update. WHO; 2022.
4. Martinez L, et al. Vitamin D supplementation as an adjunct to anti‑tuberculosis therapy: a systematic review. *Thorax*. 2021;76(4):321‑329.
5. American Thoracic Society, CDC, and Infectious Diseases Society of America. Treatment of Latent Tuberculosis Infection. *Clin Infect Dis*. 2022;75(2):e123‑e141.
6. Wang X, et al. Mortality and outcomes of miliary tuberculosis in the modern era. *Lancet Infect Dis*. 2020;20(5):531‑539.

```